• Je něco špatně v tomto záznamu ?

Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma

KR. Muthu Raja, L. Rihova, L. Zahradova, M. Klincova, M. Penka, R. Hajek,

. 2012 ; 7 (10) : e47077.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024238

Grantová podpora
NT12130 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Regulatory T (Treg) cells play an important role in the maintenance of immune system homeostasis. Multiple myeloma (MM) is a plasma cell disorder frequently associated with impaired immune cell numbers and functions. METHODS: We analyzed Treg cells in peripheral blood (n = 207) and bone marrow (n = 202) of pre-malignant and malignant MM patients using flow cytometry. Treg cells and their subsets from MM patients and healthy volunteers were functionally evaluated for their suppressive property. A cohort of 25 patients was analyzed for lymphocytes, CD4 T cells and Treg cells before and after treatment with cyclophosphamide, thalidomide plus dexamethasone (CTD). RESULTS: We found elevated frequencies of Treg cells in newly diagnosed (P<0.01) and relapsed MM patients (P<0.0001) compared to healthy volunteers. Also, Treg subsets including naïve (P = 0.015) and activated (P = 0.036) Treg cells were significantly increased in MM patients compared to healthy volunteers. Functional studies showed that Treg cells and their subsets from both MM and healthy volunteers were similar in their inhibitory function. Significantly increased frequencies of Treg cells were found in MM patients with adverse clinical features such as hypercalcemia (>10 mg/dL), decreased normal plasma cell (≤5%) count and IgA myeloma subtype. We also showed that MM patients with ≥5% of Treg cells had inferior time to progression (TTP) (13 months vs. median not reached; P = 0.013). Furthermore, we demonstrated the prognostic value of Treg cells in prediction of TTP by Cox regression analysis (P = 0.045). CTD treatment significantly reduced frequencies of CD4 T cells (P = 0.001) and Treg cells (P = 0.018) but not Treg cells/CD4 T cells ratio compared to pre-treatment. CONCLUSIONS: Our study showed immune deregulation in MM patients which is evidenced by elevated level of functionally active Treg cells and patients with increased Treg cells have higher risk of progression.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024238
003      
CZ-PrNML
005      
20170424094645.0
007      
ta
008      
130703s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0047077 $2 doi
035    __
$a (PubMed)23071717
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Muthu Raja, Karthick Raja $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. rajakarthick594@gmail.com $7 _AN046425
245    10
$a Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma / $c KR. Muthu Raja, L. Rihova, L. Zahradova, M. Klincova, M. Penka, R. Hajek,
520    9_
$a BACKGROUND: Regulatory T (Treg) cells play an important role in the maintenance of immune system homeostasis. Multiple myeloma (MM) is a plasma cell disorder frequently associated with impaired immune cell numbers and functions. METHODS: We analyzed Treg cells in peripheral blood (n = 207) and bone marrow (n = 202) of pre-malignant and malignant MM patients using flow cytometry. Treg cells and their subsets from MM patients and healthy volunteers were functionally evaluated for their suppressive property. A cohort of 25 patients was analyzed for lymphocytes, CD4 T cells and Treg cells before and after treatment with cyclophosphamide, thalidomide plus dexamethasone (CTD). RESULTS: We found elevated frequencies of Treg cells in newly diagnosed (P<0.01) and relapsed MM patients (P<0.0001) compared to healthy volunteers. Also, Treg subsets including naïve (P = 0.015) and activated (P = 0.036) Treg cells were significantly increased in MM patients compared to healthy volunteers. Functional studies showed that Treg cells and their subsets from both MM and healthy volunteers were similar in their inhibitory function. Significantly increased frequencies of Treg cells were found in MM patients with adverse clinical features such as hypercalcemia (>10 mg/dL), decreased normal plasma cell (≤5%) count and IgA myeloma subtype. We also showed that MM patients with ≥5% of Treg cells had inferior time to progression (TTP) (13 months vs. median not reached; P = 0.013). Furthermore, we demonstrated the prognostic value of Treg cells in prediction of TTP by Cox regression analysis (P = 0.045). CTD treatment significantly reduced frequencies of CD4 T cells (P = 0.001) and Treg cells (P = 0.018) but not Treg cells/CD4 T cells ratio compared to pre-treatment. CONCLUSIONS: Our study showed immune deregulation in MM patients which is evidenced by elevated level of functionally active Treg cells and patients with increased Treg cells have higher risk of progression.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a CD4-pozitivní T-lymfocyty $x účinky léků $x imunologie $7 D015496
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hyperkalcemie $x etiologie $x patologie $7 D006934
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x komplikace $x farmakoterapie $x imunologie $x patologie $7 D009101
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a referenční hodnoty $7 D012016
650    _2
$a T-lymfocyty - podskupiny $x imunologie $7 D016176
650    _2
$a regulační T-lymfocyty $x účinky léků $x imunologie $x patologie $7 D050378
650    _2
$a thalidomid $x terapeutické užití $7 D013792
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Říhová, Lucie $7 xx0081970
700    1_
$a Szeligová, Lenka $7 xx0098951
700    1_
$a Klincová, Mária $7 _AN050305
700    1_
$a Penka, Miroslav, $d 1952- $7 nlk19990073680
700    1_
$a Hájek, Roman, $d 1964- $7 nlk20000083645
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 7, č. 10 (2012), s. e47077
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23071717 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20170424095001 $b ABA008
999    __
$a ok $b bmc $g 987918 $s 822618
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 7 $c 10 $d e47077 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT12130 $p MZ0
LZP    __
$a Pubmed-20130703

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...